HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overwhelmed J&J Talc Supplier Takes Cover Under Bankruptcy Protections

Executive Summary

“It is simply not in the best interests of our stakeholders to litigate these claims in perpetuity,” says Imerys Talc America President Giorgio La Motta of the company’s decision to reorganize its business and debts under Chapter 11 in negotiation with claimants in cosmetic talc-related suits.

You may also be interested in...



J&J Starts First Baby Powder Recall Linked To Asbestos Finding

Recall announcement doesn't mention litigation J&JU faces in multiple states alleging use of Johnson's Baby Powder causes cancer due from talc in formulation. But firm's sensitivity to consumer complaints or adverse event reports linked to brand is clear with talc-related litigation as backdrop.

Tylenol Relieves Pain For J&J Consumer As Baby Care Relaunch Loses Steam

Tylenol brand boosts J&J US OTC sales 8.4% to $477m, helping balance a 24.1% decline in baby care sales due to restocking reformulated Johnson’s Baby line in 2018, mostly in the US. Firm reports consumer health sales in the US were up 1.7% to $1.39bn.

‘Toxic Beauty’ Documentary And The Growing Conversation Around ‘Clean’ Alternatives

Dermatologists and industry advocates are concerned about the public’s lack of trust in science and potentially misplaced faith in “clean” beauty, which “Toxic Beauty” screenings in the US, Canada and UK likely are only reinforcing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel